Zevra Therapeutics Inc (NASDAQ: ZVRA) has reported a loss for its third fiscal quarter (ending September 30) of $-0.40 versus a loss $-0.19 for the same period a year ago. This result fell short of […]
For its third fiscal quarter (ending September 30), Waters Corp (NYSE: WAT) has reported a -13% decline in E.P.S. from $2.61 a year ago to $2.28 in the current quarter. This result fell short of […]
Recent exceptional positive changes in investment behavior have benefitted OptimizeRX Corp (NASDAQ: OPRX): its shorter term price trend turned up, and positive upside/downside volume developed. OptimizeRX Corp (NASDAQ: OPRX) has benefited from significant positive changes […]
Xencor Inc (NASDAQ: XNCR) has reported E.P.S. of $-0.40 for its third fiscal quarter (ending September 30) versus $-0.55 for the same period a year ago. This performance was $0.31 better than the consensus estimate […]
Mercury Systems Inc (NASDAQ: MRCY) has reported a loss for its first fiscal quarter (ending September 30) of $-0.64 versus a loss $-0.26 for the same period a year ago. This result fell short of […]
For its third fiscal quarter (ending September 30), National Research Corp (NASDAQ: NRC) has reported a -6% decline in E.P.S. from $0.34 a year ago to $0.32 in the current quarter. E.P.S. were $1.17 for […]
The Hain Celestial Group Inc (NASDAQ: HAIN) has reported a loss for its first fiscal quarter (ending September 30) of $-0.12 versus $0.08 for the same period a year ago — a decline of -250%. […]
On 11/7/23, Axogen Inc (NASDAQ: AXGN) stock enjoyed a major increase of 36.9%, closing at $5.38. Relative to the market the stock has been extremely weak over the last nine months but has risen 42.3% […]
TripAdvisor Inc (NASDAQ: TRIP) stock closed at $17.88 on 11/7/23 after a major increase of 11.0%. The stock has risen 23.5% during the last week but has been weak relative to the market over the […]
For its third fiscal quarter (ending September 30), Sage Therapeutics Inc (NASDAQ: SAGE) has reported E.P.S. of $-3.37 compared to $-2.31 a year ago. Relative to the consensus estimate of $-2.69, this was a shortfall […]
Privacy Statement Terms Of Use ©2024 PriceTarget Research